All In Biotech

Investigational drug · Phase 2

YL-13027

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Pancreatic Cancer.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 29, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

5

Any phase or sponsor naming "YL-13027"

First trial start

2024

Nov 30, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "YL-13027", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Pancreatic Cancer

Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "YL-13027" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Metastatic Pancreatic Cancer

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • SetidegrasibASP3082Phase 32 trials

    Astellas · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

  • SurufatinibPhase 31 trial

    Hutchmed · Metastatic Pancreatic Cancer

  • BalstilimabAGEN2034Phase 23 trials

    ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer

  • Olaptesed pegolNOX-A12Phase 22 trials

    TME Pharma AG · Metastatic Pancreatic Cancer, Glioblastoma

  • ZalifrelimabPhase 22 trials

    ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer

  • HY-0102Phase 21 trial

    Shanghai YingLi Pharmaceutical Co. Ltd. · Metastatic Pancreatic Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.